Rizatriptan
Rizatriptan is a triptan medicine taken at the start of a migraine attack to treat migraine with or without aura in adults and children 6 to 17, available as tablets, orally disintegrating tablets and a dissolving oral film.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 54 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Rizatriptan (Maxalt) is a fast-acting triptan, a usual first-choice prescription for stopping a migraine attack once it starts (not for preventing attacks), that works on serotonin receptors in the blood vessels and pain nerves of the head, and it has been on the market since about 1998 and is available generically. Most people tolerate it well, though some notice brief tiredness, sleepiness or dizziness, or a tight, heavy feeling in the chest, throat or jaw that is usually not from the heart. Because it can narrow blood vessels, it is not safe for people with heart disease, a past stroke or uncontrolled high blood pressure, and chest pressure that feels heart-related needs emergency help.
Clinical pearls
- If you take propranolol, tell your prescriber, because it raises rizatriptan levels and the dose must be adjusted.
- Never take it within 2 weeks of an MAO inhibitor, or within 24 hours of another triptan or an ergot medicine.
- On SSRI, SNRI or tricyclic antidepressants, watch for agitation, fever, fast heartbeat or twitching, signs of serotonin syndrome.
- Treating headaches on 10 or more days a month can cause medication overuse headache, so track how often you use it.
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
BOXED WARNING
Read the full warning on DailyMed →Patient information guide A plain-language walkthrough of Rizatriptan, written from its FDA label.
What Rizatriptan is used for
▾
Rizatriptan treats migraine attacks once they have begun.
- Acute treatment of migraine with or without aura in adults and children 6 to 17 (tablets, orally disintegrating tablets including Maxalt-MLT, and Rizafilm oral film).
- Not for preventing migraine.
- Not indicated for cluster headache, or for hemiplegic or basilar migraine.
How Rizatriptan works
▾
Rizatriptan is a triptan. It binds tightly to serotonin 5-HT 1B/1D receptors on blood vessels inside the head and on trigeminal pain nerves. This is believed to be how it eases migraine headache.
Rizatriptan dosage
▾
Rizatriptan is taken by mouth as a single dose at the start of a migraine. A repeat dose may be taken at least 2 hours later if the headache returns, up to a daily maximum.
- Tablets are swallowed. Orally disintegrating tablets and Rizafilm dissolve in the mouth, and Rizafilm goes on the tongue.
- It can be taken with or without food.
- Children's doses depend on weight. Safety of more than one dose in 24 hours in children has not been established.
- Safety of treating more than about four headaches in 30 days has not been established.
Follow your prescriber and label directions.
Dosing details from the FDA-approved label
From the Rizatriptan prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Adults (acute treatment of migraine)
- 5 mg or 10 mg single dose
- If the migraine headache returns, a second dose may be administered 2 hours after the first dose
- Separate repeat doses by at least two hours
- Maximum: 30 mg in any 24-hour period
- The 10 mg dose may provide a greater effect than the 5 mg dose, but may have a greater risk of adverse reactions; safety of treating, on average, more than four headaches in a 30-day period has not been established
- Pediatric patients 6 to 17 years weighing less than 40 kg (88 lb)
- 5 mg single dose
- Efficacy and safety of more than one dose within 24 hours have not been established; not to be prescribed to propranolol-treated patients weighing less than 40 kg (88 lb)
- Pediatric patients 6 to 17 years weighing 40 kg (88 lb) or more
- 10 mg single dose
- Efficacy and safety of more than one dose within 24 hours have not been established
- Adult patients taking propranolol
- Only the 5 mg dose is recommended, up to a maximum of 3 doses in any 24-hour period
- Maximum: 15 mg in a 24-hour period (3 doses)
- Dose adjustment for propranolol co-administration
- Pediatric patients weighing 40 kg (88 lb) or more taking propranolol
- Only a single 5 mg dose is recommended
- Maximum: 5 mg in a 24-hour period
- Dose adjustment for propranolol co-administration
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION • Adults: 5 mg or 10 mg single dose; separate repeat doses by at least two hours; maximum dose in a 24-hour period: 30 mg ( 2.1 ) • Pediatric patients 6 to 17 years: 5 mg single dose in patients less than 40 kg (88 lb); 10 mg single dose in patients 40 kg (88 lb) or more ( 2.2 ) • Adjust dose if co-administered with propranolol ( 2.4 ) 2.1 Dosing Information in Adults The recommended starting dose of rizatriptan benzoate orally disintegrating tablets, USP is either 5-mg or 10-mg for the acute treatment of migraines in adults. The 10 mg dose may provide a greater effect than the 5 mg dose, but may have a greater risk of adverse reactions [see Clinical Studies ( 14.1 )] . Redosing in Adults Although the effectiveness of a second dose or subsequent doses has not been established in placebo-controlled trials, if the migraine headache returns, a second dose may be administered 2 hours after the first dose. The maximum daily dose should not exceed 30 mg in any 24-hour period. The safety of treating, on average, more than four headaches in a 30-day period has not been established. 2.2 Dosing Information in Pediatric Patients (Age 6 to 17 Years) Dosing in pediatric patients is based on the patient's body weight. The recommended dose of rizatriptan benzoate orally disintegrating tablets is 5 mg in patients weighing less than 40 kg (88 lb), and 10 mg in patients weighing 40 kg (88 lb) or more. The efficacy and safety of treatment with more than one dose of rizatriptan benzoate orally disintegrating tablets within 24 hours in pediatric patients 6 to 17 years of age have not been established. 2.3 Administration of Rizatriptan Benzoate Orally Disintegrating Tablets USP For rizatriptan benzoate Orally Disintegrating Tablets, USP, administration with liquid is not necessary. Orally disintegrating tablets are packaged in a blister within a carton and patients should not remove the tablet from the blister until just prior to dosing. The blister pack should then be peeled open with dry hands and the orally disintegrating tablet placed on the tongue, where it will dissolve and be swallowed with the saliva.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Rizatriptan side effects
▾
The most common side effects in adults were:
Common side effects
- Tiredness or weakness (asthenia/fatigue)
- Sleepiness (somnolence)
- Pain or pressure sensations
- Dizziness
- Unusual sensations such as tingling (paresthesia)
When to get medical help
- Get emergency help for chest pain or pressure, or tightness in the throat, neck or jaw that you think may be heart-related.
- Get emergency help for signs of a stroke or brain bleed, such as sudden weakness, trouble speaking or severe sudden headache.
- Seek help for a racing or irregular heartbeat.
- Seek help for stomach pain with bloody diarrhea, or cold, numb or painful fingers or toes.
- Seek help for possible serotonin syndrome: agitation, hallucinations, fast heartbeat, fever, muscle twitching or stiffness, nausea, vomiting or diarrhea.
- Seek help for swelling of the face or throat or trouble breathing, which can be signs of a serious allergic reaction.
- Call your doctor if you have vision loss or headaches that become more frequent from using migraine medicines too often.
Rizatriptan warnings and precautions
▾
- Heart risks: heart attack, angina and dangerous heart rhythms have been reported. People with several heart risk factors need a heart check first.
- Stroke and brain bleeds: some cases were fatal. Some happened when other symptoms were mistaken for migraine.
- Reduced blood flow: can affect the gut, spleen, hands and feet. Vision loss has been reported.
- Blood pressure: significant rises have occurred rarely.
- Medication overuse headache: from using migraine medicines 10 or more days a month.
- Serotonin syndrome: especially with antidepressants.
Rizatriptan interactions
▾
Several medicines change how rizatriptan works or add risk.
- Propranolol: raises rizatriptan levels, so dose adjustment is needed.
- MAO inhibitors: raise levels, so they are not allowed together or within 2 weeks.
- Other triptans and ergot medicines: additive blood vessel narrowing, so keep 24 hours apart.
- SSRIs, SNRIs, tricyclics: risk of serotonin syndrome.
Interactions listed in the FDA-approved label
From the Rizatriptan prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Propranolol: Propranolol increased the plasma AUC of rizatriptan by 70% (a four-fold increase was observed in one subject); the AUC of the active N-monodesmethyl metabolite was not affected. Adjust the rizatriptan dose in propranolol-treated patients (see dosing).
- Ergot-containing drugs (ergotamine, dihydroergotamine, methysergide): Ergot-containing drugs have been reported to cause prolonged vasospastic reactions, and these effects may be additive. Use within 24 hours of rizatriptan is contraindicated.
- Other 5-HT1 agonists: Vasospastic effects may be additive. Co-administration within 24 hours of each other is contraindicated.
- SSRIs/SNRIs: Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs or SNRIs.
- Monoamine oxidase inhibitors (MAO-A inhibitors and non-selective MAO inhibitors): A specific MAO-A inhibitor (moclobemide) increased rizatriptan AUC by 119% and Cmax by 41%, and the AUC of the active N-monodesmethyl metabolite by more than 400%. Rizatriptan is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors.
- Selective MAO-B inhibitors: No pharmacokinetic interaction is anticipated.
- Nadolol/Metoprolol: No pharmacokinetic interactions were observed with nadolol 80 mg or metoprolol 100 mg every 12 hours and a single 10 mg dose of rizatriptan.
- Paroxetine: Paroxetine 20 mg/day for two weeks did not affect plasma concentrations of rizatriptan or its safety profile.
- Oral contraceptives: Rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone.
Read the label’s full interactions text
7 DRUG INTERACTIONS 7.1 Propranolol The dose of rizatriptan benzoate should be adjusted in propranolol-treated patients, as propranolol has been shown to increase the plasma AUC of rizatriptan by 70% [see Dosage and Administration ( 2.4 ) and Clinical Pharmacology ( 12.3 )] . 7.2 Ergot-Containing Drugs Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and rizatriptan benzoate within 24 hours is contraindicated [see Contraindications ( 4 )] . 7.3 Other 5-HT 1 Agonists Because their vasospastic effects may be additive, co-administration of rizatriptan benzoate and other 5-HT 1 agonists within 24 hours of each other is contraindicated [see Contraindications ( 4 )] . 7.4 SSRIs/SNRIs and Serotonin Syndrome Cases of serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see Warnings and Precautions ( 5.7 )] . 7.5 Monoamine Oxidase Inhibitors Rizatriptan benzoate is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. A specific MAO-A inhibitor increased the systemic exposure of rizatriptan and its metabolite [see Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )] .
Drug Interactions [See also Drug Interactions ( 7 )]. Monoamine oxidase inhibitors: Rizatriptan is principally metabolized via monoamine oxidase, ‘A’ subtype (MAO-A). Plasma concentrations of rizatriptan may be increased by drugs that are selective MAO-A inhibitors (e.g., moclobemide) or nonselective MAO inhibitors [type A and B] (e.g., isocarboxazid, phenelzine, tranylcypromine, and pargyline).
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Rizatriptan
▾
- Do not use with heart disease, past stroke or TIA, peripheral vascular disease, ischemic bowel disease or uncontrolled high blood pressure.
- Do not use for hemiplegic or basilar migraine, or with an allergy to rizatriptan.
- Pregnancy: human data are limited, and animal studies showed harm at high exposures.
- Breastfeeding: no human milk data. Discuss benefits and risks with your doctor.
- Children under 6: not established.
- Older adults: start at the low end, and get a heart evaluation if you have risk factors.
- Orally disintegrating tablets contain phenylalanine.
Rizatriptan overdose
▾
In studies, higher doses caused dizziness and sleepiness. At much higher doses some people had fainting, slow heart rate, vomiting or loss of bladder control. High blood pressure or reduced heart blood flow could occur. Seek emergency care. Monitoring for at least 12 hours is advised.
What Rizatriptan does in the body
▾
Rizatriptan binds with high affinity to 5-HT 1B/1D receptors on blood vessels in the head and on trigeminal sensory nerves, which is thought to relieve migraine headache. Maximal doses caused only slight blood pressure increases of about 2 to 3 mmHg in healthy adults.
How your body processes Rizatriptan
▾
Rizatriptan is well absorbed by mouth, with peak levels in about 1 to 1.5 hours. Food delays the peak by about an hour but does not change how much is absorbed. It is mostly broken down by the enzyme MAO-A and cleared mainly through urine. Its half-life is about 2 to 3 hours.
How to store Rizatriptan
▾
Store at 20º to 25ºC (68º to 77ºF).
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Rizatriptan
38 supplements and herbal products have documented interactions with Rizatriptan in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 2
- Moderate · 25
- Minor · 11
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Rizatriptan: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Rizatriptan — the kind of thing our pharmacy team would talk through with you at the counter.
What is rizatriptan for?
▾
How do I take it?
▾
What side effects should I expect?
▾
When should I get help right away?
▾
Can I take it with my other medicines?
▾
Is it safe in pregnancy?
▾
Is Rizatriptan available over the counter?
▾
When was Rizatriptan first available?
▾
Who makes Rizatriptan?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Rizatriptan on HelloPharmacist
Rizatriptan forms and strengths (how it comes)
Rizatriptan is available in 3 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Rizatriptan inactive ingredients by manufacturer.
Tablet
How this form is used
- Maxalt and rizatriptan benzoate tablets are used for acute treatment of migraine with or without aura in adults and children 6 to 17.
- These tablets are not for migraine prevention or hemiplegic or basilar migraine.
- Rizatriptan benzoate tablets: repeat doses are at least 2 hours apart, within a daily maximum.
- Rizatriptan benzoate tablets: only the lower dose is used in adults taking propranolol, per the label's adjustment.
- Rizatriptan benzoate tablets: children's dose depends on body weight.
Orally disintegrating tablet
How this form is used
- Maxalt-MLT and rizatriptan benzoate orally disintegrating tablets are used for acute treatment of migraine with or without aura in adults and children 6 to 17.
- These tablets are not for migraine prevention or hemiplegic or basilar migraine.
- Rizatriptan benzoate orally disintegrating tablets: repeat doses are at least 2 hours apart, within a daily maximum.
- Rizatriptan benzoate orally disintegrating tablets contain phenylalanine, which matters for people with phenylketonuria.
- Rizatriptan benzoate orally disintegrating tablets are absorbed somewhat more slowly than regular tablets.
Dissolving oral film
How this form is used
- Rizafilm is used for acute treatment of migraine with or without aura in adults and children 6 to 17.
- Rizafilm is not for preventing migraine or for cluster headache.
- Rizafilm is placed on the tongue, and taking it with liquid is not necessary.
- Rizafilm repeat doses must be at least 2 hours apart, within a daily maximum.
- Rizafilm comes in individual child-resistant pouches with a tear notch.
- Rizafilm dosing for children 6 to 17 depends on body weight.
Rizatriptan on the U.S. market: products, makers and brands
How Rizatriptan appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
23 companies list 72 Rizatriptan product records with the FDA, mostly as tablet, orally disintegrating tablet, dissolving oral film; the earliest marketing or approval year on record is 1998. Brand names on the directory include Maxalt-mlt, Maxalt, Rizafilm and 2 more; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (13) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Rizatriptan is used (Medicaid data)
A general measure of how commonly Rizatriptan is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Rizatriptan is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Rizatriptan prescribed? Of the 1,601 medications we measure, Rizatriptan ranks #209 by Medicaid prescriptions — more than 87% of them.
Utilization by Rizatriptan product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
rizatriptan 10 MG Oral Tablet Most dispensed
Summed across the 8 of 83 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 314209
rizatriptan 10 MG Disintegrating Oral Tablet
Summed across the 8 of 57 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 312837
rizatriptan 5 MG Oral Tablet
Summed across the 8 of 70 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 312840
rizatriptan 5 MG Disintegrating Oral Tablet
Summed across the 6 of 44 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 312839
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Rizatriptan, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 30 of 254 listed Rizatriptan NDCs with Medicaid activity.
Compare Rizatriptan products
A representative set of FDA-listed product records for Rizatriptan — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Dissolving oral film | ||||
| 10 mg | Oral | A-S Medication Solutions | NDA | View NDC → |
| 5 mg | Oral | Gensco Laboratories LLC | NDA | View NDC → |
| 10 mg | Oral | Gensco Laboratories LLC | NDA | View NDC → |
| 💊Orally disintegrating tablet | ||||
| 10 mg | Oral | Advanced Rx of Tennessee, LLC | ANDA | View NDC → |
| 5 mg | Oral | Asclemed USA, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Asclemed USA, Inc. | ANDA | View NDC → |
| 5 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 10 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 5 mg | Oral | Bionpharma Inc., | ANDA | View NDC → |
| 10 mg | Oral | Bionpharma Inc., | ANDA | View NDC → |
| 10 mg | Oral | Bryant Ranch Prepack × 2 listings | ANDA | View NDC → |
| 5 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 10 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 10 mg | Oral | Direct Rx | ANDA | View NDC → |
| 10 mg | Oral | Direct_rx | ANDA | View NDC → |
| 5 mg | Oral | Glenmark Pharmaceuticals Inc., USA | ANDA | View NDC → |
| 10 mg | Oral | Glenmark Pharmaceuticals Inc., USA | ANDA | View NDC → |
| 5 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 5 mg | Oral | Macleods Pharmaceuticals Limited | ANDA | View NDC → |
| 10 mg | Oral | Macleods Pharmaceuticals Limited | ANDA | View NDC → |
| 10 mg | Oral | NuCare Pharmaceuticals,Inc. | ANDA | View NDC → |
| 10 mg | Oral | Organon LLC | NDA | View NDC → |
| 5 mg | Oral | Panacea Biotec Limited | ANDA | View NDC → |
| 10 mg | Oral | Panacea Biotec Limited | ANDA | View NDC → |
| 10 mg | Oral | Proficient Rx LP × 2 listings | ANDA | View NDC → |
| 10 mg | Oral | Remedyrepack Inc. | ANDA | View NDC → |
| 5 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 5 mg | Oral | Unichem Pharmaceuticals (USA), Inc. | ANDA | View NDC → |
| 10 mg | Oral | Unichem Pharmaceuticals (USA), Inc. | ANDA | View NDC → |
| 💊Tablet | ||||
| 10 mg | Oral | A-S Medication Solutions × 3 listings | ANDA | View NDC → |
| 5 mg | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 10 mg | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 5 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 10 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 5 mg | Oral | Bryant Ranch Prepack × 4 listings | ANDA | View NDC → |
| 10 mg | Oral | Bryant Ranch Prepack × 3 listings | ANDA | View NDC → |
| 5 mg | Oral | Cipla USA Inc. | ANDA | View NDC → |
| 10 mg | Oral | Cipla USA Inc. | ANDA | View NDC → |
| 5 mg | Oral | Creekwood Pharmaceuticals LLC | ANDA | View NDC → |
| 10 mg | Oral | Creekwood Pharmaceuticals LLC | ANDA | View NDC → |
| 5 mg | Oral | Direct Rx × 2 listings | ANDA | View NDC → |
| 10 mg | Oral | Direct Rx × 2 listings | ANDA | View NDC → |
| 5 mg | Oral | Direct_Rx | ANDA | View NDC → |
| 10 mg | Oral | Direct_Rx | ANDA | View NDC → |
| 5 mg | Oral | Glenmark Pharmaceuticals Inc., USA | ANDA | View NDC → |
| 10 mg | Oral | Glenmark Pharmaceuticals Inc., USA | ANDA | View NDC → |
| 5 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 5 mg | Oral | Macleods Pharmaceuticals Limited | ANDA | View NDC → |
| 10 mg | Oral | Macleods Pharmaceuticals Limited | ANDA | View NDC → |
| 10 mg | Oral | Organon LLC | NDA | View NDC → |
| 10 mg | Oral | Proficient Rx LP × 2 listings | ANDA | View NDC → |
| 5 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 5 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 5 mg | Oral | Unichem Pharmaceuticals (USA), Inc. | ANDA | View NDC → |
| 10 mg | Oral | Unichem Pharmaceuticals (USA), Inc. | ANDA | View NDC → |
Showing 72 of 72 products — FDA National Drug Code Directory. See every product, package size and price: browse all 72 Rizatriptan NDCs →
Rizatriptan side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Rizatriptan — a signal of what to watch for, not proof the drug caused it.
The effects most often named in FDA reports that mention Rizatriptan are nausea, headache, migraine; about 58% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Rizatriptan in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Rizatriptan FDA approval history
How Rizatriptan went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Rizatriptan was first approved by the FDA in 1998 (Brand: MAXALT · Organon Llc); the first generic version was approved in 2012. It remains available in U.S. pharmacies today.
Source: Drugs@FDA.
Rizatriptan recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list 4 Rizatriptan recalls since July 2021, covering 9 product listings. Three of them are still ongoing or began in the last six months and are listed first. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.
- Rizatriptan Benzoate Tablets, USP, 10 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories LLC, Parsippany, NJ 07054, NDC 6787… Lots: Lot 22143653, 22143675, Exp Date: July 2025; Lot 22144528, Exp Date: September 2025; Lot 22144977, Exp Date: November 2025; Lot 23140257, Exp Date: December 2025; Lot 23140999, Exp Date: Feb. 2026; Lot 23141900, 23142118, 23142120, 2314212… FDA record D-0534-2025 →
- Rizatriptan Benzoate Tablets, USP, 5 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories LLC, Parsippany, NJ 07054, NDC 67877… Lots: Lot 23142117, 23142119, 23142122, Exp Date: May 2026; Lot 24142625, Exp Date: Jun. 2027 FDA record D-0533-2025 →
- Rizatriptan Benzoate Orally Disintegrating Tablets, USP 10mg, 18 (3 x 6) Unit-Dose Tablets, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, Product of India, NDC 68462-468-06 Lots: Lot#: 19223402; Exp. 7/2024 Lot#: 19224858; Exp. 11/2024 Lot#: 19232492; Exp. 6/2025 FDA record D-0535-2024 →
- Rizatriptan Benzoate Orally Disintegrating Tablets, USP 5mg, 18 (3 x 6) Unit-Dose Tablets, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, Product of India, NDC 68462-467-06 Lots: Lot#: 19224857; Exp. 11/2024 Lot#: 19232493; Exp. 6/2025 FDA record D-0534-2024 →
- Rizatriptan Benzoate Tablets USP, 10 mg, 18 (3 X 6) Unit-Dose Tablets, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430 Product of India, NDC 68462-466-99 Lots: Lot#: 19224217; Exp. 9/2024 Lot#: 19233789; Exp. 9/2025 Lot#: 19224444; Exp. 9/2024 FDA record D-0533-2024 →
- Rizatriptan Benzoate Tablets USP, 5mg, 18 (3 X 6) Unit-Dose Tablets, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430 Product of India, NDC 68462-465-99 Lots: Lot#: 19233788; Exp. 9/2025 Lot#: 19224445; Exp. 9/2024 FDA record D-0532-2024 →
- Rizatriptan Benzoate Orally Disintegrating Tablets 10mg, 18 Tablets (3 x 6 Unit-Dose Tablets) Blister Packs, Rx only, Manufactured for: Macleods Pharma USA Inc. Plainsboro, NJ 08536, Manufactured by:… Lots: Lot #: BRM2111A, BRM2112A, BRM2113A, BRM2114A, BRM2115A, BRM2116A, exp. date 04/2025 FDA record D-0080-2022 →
- Rizatriptan Benzoate Orally Disintegrating Tablets 5mg, 12 Tablets (2 x 6 Unit-Dose Tablets) Blister Packs, Rx only, Manufactured for: Macleods Pharma USA Inc. Plainsboro, NJ 08536, Manufactured by:… Lots: Lot #: BRL2102A, BRL2103A, exp. date 04/2025 FDA record D-0079-2022 →
- Rizatriptan Benzoate Film Coated Tablets, 10 mg, packaged in a) 12 Tablets (2X6 Unit-Dose Tablets) Blister Packs, NDC 33342-088-45), b) 18 Tablets (3 x 6 Unit-Dose Tablets, NDC 33342-088-41) Rx only,… Lots: Lot #: BRJ2112A, BRJ2113A, BRJ2114A, BRJ2114B, exp. date 04/2024 FDA record D-0078-2022 →
Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 88014 3 dose forms · 6 strengths
-
Dose form (SCDF) Disintegrating Oral Tablet RxCUI 374590In current FDA listings -
Dose form (SCDF) Oral Film RxCUI 2634481In current FDA listings -
Dose form (SCDF) Oral Tablet RxCUI 373798In current FDA listings
Look up RxCUI 88014 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Rizatriptan supply and shortage status
Whether Rizatriptan is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Rizatriptan costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet · Oral | 10 mg | $0.335 per tablet | NDC details & price history |
| Tablet · Oral | 5 mg | $0.348 per tablet | NDC details & price history |
| Tablet, Orally Disintegrating · Oral | 10 mg | $0.654 per tablet | NDC details & price history |
| Tablet, Orally Disintegrating · Oral | 5 mg | $0.805 per tablet | NDC details & price history |
| Tablet, Film Coated · Oral | 10 mg | $0.335–$0.366 per tablet | NDC details & price history |
| Tablet, Film Coated · Oral | 5 mg | $0.348–$0.514 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Rizatriptan brand names
Rizatriptan is sold under 5 brand names in the FDA directory — Maxalt-mlt, Maxalt, Rizafilm, Rizatriptan Benzoate and others. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Rizatriptan: manufacturers and labelers
23 companies list Rizatriptan products with the FDA. By number of product records, the largest are Bryant Ranch Prepack, Direct Rx, A-S Medication Solutions. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Rizatriptan drug class (RxNorm)
Rizatriptan belongs to the Serotonin-1b and Serotonin-1d Receptor Agonist class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Rizatriptan page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Macleods Pharmaceuticals Limited is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →